Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03190278 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1 study of Relapsed/Refractory Acute Myeloid Leukemia, sponsored by Cellectis S.A..
- Active
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 8
- Study locations
NCT03190278: Active Phase 1 study of Relapsed/Refractory Acute Myeloid Leukemia, sponsored by Cellectis S.A..
NCT03190278 is a Phase 1 study of Relapsed/Refractory Acute Myeloid Leukemia that is active but no longer recruiting, run by Cellectis S.A.. The registered enrollment target is 29 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03190278, a Phase 1 study of Relapsed/Refractory Acute Myeloid Leukemia, is active but no longer recruiting, sponsored by Cellectis S.A..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 8
- Study locations
Study Summary
Phase I, open-label, dose-escalation and dose-expansion study evaluating the safety and efficacy of Universal Chimeric Antigen Receptor T-cell (UCART) targeting the Cluster of Differentiation 123 (CD123) in patients with relapsed/refractory acute myeloid leukemia (AML). The purpose of this study is to evaluate the safety and clinical activity of Universal Chimeric Antigen Receptor T-cells targeting CD123 (UCART123v1.2) and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).
Primary Outcome
Safety of UCART123v1.2 - Incidence, nature, and severity of AE and SAEs throughout the study
Conditions Studied
Interventions
- BIOLOGICAL UCART123v1.2
Study Locations (8)
New York
- Roswell Park Cancer Institute - Buffalo
- Weill Medical College of Cornell University - New York
California
- University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center - San Francisco
Florida
- H. Lee Moffitt Cancer Center & Research Institute - Tampa
Illinois
- Northwestern University - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
Pennsylvania
- University of Pennsylvania - Abramson Cancer Center - Philadelphia
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2017-06-19 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
What the registry record for NCT03190278 still lists
NCT03190278 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Relapsed/Refractory Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which UCART123v1.2 is the first listed.
NCT03190278 lists 8 locations in 7 states (New York, California, Florida).
Frequently Asked Questions
What is clinical trial NCT03190278 about?
NCT03190278 is a clinical study titled "Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia". Phase I, open-label, dose-escalation and dose-expansion study evaluating the safety and efficacy of Universal Chimeric Antigen Receptor T-cell (UCART) targeting the Cluster of Differentiation 123 (CD123) in patients with relapsed/refractory acute myeloid leukemia (AML). The purpose of this study is ...
What is the current status of trial NCT03190278?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2017-06-19. Estimated completion is 2025-12.
What conditions does trial NCT03190278 study?
This clinical trial studies the following conditions: Relapsed/Refractory Acute Myeloid Leukemia.
What interventions are being tested in trial NCT03190278?
The interventions under investigation include: UCART123v1.2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03190278?
This trial is sponsored by Cellectis S.A., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03190278 being conducted?
This trial has 8 study locations across California, Florida, Illinois, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed/Refractory Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03190278's enrollment target sits among peer trials
29 1440th of 2000 higher than 554 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI